Novo CEO after hearing: PBMs do not tell the entire truth about the system

US pharmacy benefit managers only tell half the truth when they say that they have no influence on Novo Nordisk's insulin list prices, says the CEO of the Danish pharmaceutical company.

Photo: Ritzau Scanpix/ERH/Niels Hougaard

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles